跳至主要内容
临床试验/EUCTR2019-002873-80-ES
EUCTR2019-002873-80-ES进行中(未招募)1 期

nicentre, open, uncontrolled clinical trial to assess the morphological, biochemical and functional effects of Diflunisal treatment in patients with transthyretin cardiac amyloidosis

FUNDACION JIMENEZ DIAZ HEALTH RESEARCH INSTITUTE0 个研究点目标入组 20 人开始时间: 2019年11月11日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • 1. Patients over 18 years old
  • 2. Diagnosed of cardiac amyloidosis by TTR by cardiac uptake grade 2 or 3 in a scintigraphy performed with Tc-DPD in the absence of monoclonal scintigraphy or by myocardial biopsy with positive immunofixation in the case of presenting peripheral blood gamma pathia.
  • 3. Acceptance and signing of consent for the study after receiving the appropriate information.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 15
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 5

排除标准

  • 1. Known allergy or hypersensitivity to diflunisal or any of its components, or to drugs from the group of non-steroidal anti-inflammatory drugs.
  • 2. History of acute episodes of asthma, hives, rhinitis or angioedema in relation to ibuprofen, aspirin or other NSAIDs.
  • 3. History or active episode of gastrointestinal bleeding or perforation related to previous treatment with NSAIDs.
  • 4. Severe heart failure (NYHA functional class IV)
  • 5. Severe renal impairment: Glomerular filtration estimated <30mL / min / 1.73 m2 calculated by the CKD-EPI formula.
  • 6. Survival <1 year due to some known comorbidity
  • 7. Concomintant treatment with 2 antiplatelet agents associated with 1 anticoagulant
  • 8. Previous liver or heart transplantation
  • 9. Hepatic dysfunction (ALT / AST or BT above 3 times the upper limit of normal)
  • 10. Platelets <100,000 / mm3
  • 11. Potentially fertile women who are not willing to use a contraceptive method that is considered effective
  • 12. Pregnancy or breastfeeding
  • 13. Participants in another clinical trial with medication in the 28 days prior to the start of recruitment.
  • 14. At the discretion of the investigator, the patient's inability to understand or comply with the study procedures

研究者

发起方
FUNDACION JIMENEZ DIAZ HEALTH RESEARCH INSTITUTE

相似试验